Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Liver save search
BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company’s Ascites Phase 2 Trial Accepted for Presentation at AASLD – The Liver Meeting® 2023
Published: 2023-10-26 (Crawled : 12:00) - globenewswire.com
BIVI | $0.5087 3.44% 750K
|
Health Technology
|
| O: -3.49%
H: 6.58%
C: 6.25%
meeting liver presentation trial
Aligos Therapeutics To Present Late Breaking Poster on ALG-000184, its CAM-E Drug Candidate, at The Liver Meeting® 2023
Published: 2023-10-25 (Crawled : 12:00) - globenewswire.com
ALGS | $0.8503 3.24% 530K
|
Health Technology
|
| O: 0.16%
H: 3.13%
C: 0.75%
alg-0001 meeting drug liver therapeutics
Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023
Published: 2023-10-25 (Crawled : 12:00) - globenewswire.com
ALT | $7.125 -5.88% 1.4M
|
Commercial Services
|
| O: 2.12%
H: 1.45%
C: -1.66%
meeting liver presentation
Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023
Published: 2023-10-24 (Crawled : 15:30) - globenewswire.com
SGMT | News | $4.12 -3.74% 140K
|
Health Technology
|
| O: -1.98%
H: 5.62%
C: -2.47%
meeting liver
Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
Published: 2023-10-19 (Crawled : 12:00) - globenewswire.com
PLRX | $12.01 -4.07% 160K
|
Health Technology
|
| O: -0.3%
H: 3.26%
C: 2.74%
meeting liver presentation bexotegrast therapeutics
CymaBay’s RESPONSE Phase 3 Data Evaluating Seladelpar for Primary Biliary Cholangitis to be Featured in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
Published: 2023-10-18 (Crawled : 12:00) - globenewswire.com
CBAY | $32.48 0.03% 8.4M
|
Health Technology
|
| O: -0.98%
H: 0.0%
C: -3.73%
meeting liver presentation response
Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)
Published: 2023-10-13 (Crawled : 12:00) - globenewswire.com
THTX | $1.29 -12.78% 8.1K
|
Health Technology
|
| O: -6.63%
H: 11.24%
C: 4.14%
liver hiv week
Omega Therapeutics Announces Two Poster Presentations on Liver Inflammation and Fibrosis at AASLD’s The Liver Meeting® 2023
Published: 2023-10-11 (Crawled : 20:00) - globenewswire.com
OMGA | $2.33 -0.43% 130K
|
|
| O: 1.56%
H: 0.0%
C: -8.21%
meeting liver fibrosis therapeutics
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023
Published: 2023-10-11 (Crawled : 12:00) - globenewswire.com
ABUS | $2.755 0.18% 170K
|
Health Technology
|
| O: 5.41%
H: 0.51%
C: -4.1%
meeting liver presentation
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
Published: 2023-10-11 (Crawled : 12:00) - globenewswire.com
ASMB | $13.48 1.58% 5.4K
|
Health Technology
|
| O: -4.16%
H: 11.6%
C: 5.71%
meeting liver
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
Published: 2023-10-11 (Crawled : 12:00) - globenewswire.com
VIR | $8.08 -0.62% 450K
|
Health Technology
|
| O: -0.9%
H: 2.27%
C: 0.68%
ALNY | $144.31 -1.21% 200K
|
Health Technology
|
| O: -1.16%
H: 1.43%
C: 0.43%
meeting hepatitis liver presentation
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase in Chronic Liver Disease and Cirrhosis-Related Deaths Marking These as Ninth Leading Cause of Death in U.S.
Published: 2023-10-10 (Crawled : 13:30) - biospace.com/
BHC | $8.56 0.35% 590K
|
Health Technology
|
| O: 1.18%
H: 1.81%
C: 0.52%
liver disease report health pharmaceuticals trends
Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins
Published: 2023-10-10 (Crawled : 11:00) - globenewswire.com
AKRO | $20.3 -3.33% 240K
|
Health Technology
|
| O: -59.06%
H: 0.0%
C: -8.66%
liver fibrosis therapeutics results insulin nash
Better Therapeutics Announces Publication of LivVita Liver Disease Study Results in Gastro Hep Advances
Published: 2023-10-05 (Crawled : 12:00) - biospace.com/
BTTX | $0.006 340K
|
|
| O: 1.13%
H: 5.96%
C: -7.68%
liver disease publication therapeutics results study
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis
Published: 2023-10-03 (Crawled : 12:00) - globenewswire.com
GALT | $3.29 -2.66% 120K
|
Health Technology
|
| O: -2.08%
H: 3.72%
C: 3.19%
cirrhosis liver positive meeting hypertension therapeutics study
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: -1.24%
H: 0.0%
C: 0.0%
PLRX | $12.01 -4.07% 160K
|
Health Technology
|
| O: 7.89%
H: 11.25%
C: 5.98%
liver positive fibrosis bexotegrast trial therapeutics
Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
GALT | $3.29 -2.66% 120K
|
Health Technology
|
| O: 0.0%
H: 3.24%
C: -1.63%
cirrhosis liver update program therapeutics
Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
ICPT | $19.0 -0.05% 4M
|
Health Technology
|
| O: 76.15%
H: 1.79%
C: 1.74%
rare liver pharmaceuticals global acquire
Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer
Published: 2023-09-19 (Crawled : 13:00) - globenewswire.com
HEPA | $1.39 -6.71% 22K
|
Health Technology
|
| O: 1.97%
H: 8.1%
C: 2.64%
liver cancer pharmaceuticals
Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis
Published: 2023-09-13 (Crawled : 13:00) - globenewswire.com
MDGL | $208.64 -4.46% 230K
|
Health Technology
|
| O: 6.58%
H: 2.57%
C: 1.02%
drug liver review treatment fibrosis pharmaceuticals application nash
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
CZOO | $10.52 110.82% 10M
|
CSSE 4 | $0.3181 108.86% 170M
|
Consumer Services
BOF | $1.87 59.83% 100M
|
AMST | $3.1 55.0% 66M
|
Technology Services
LICN | $0.85 51.79% 13M
|
WIMI | $1.03 41.99% 15M
|
Technology Services
SKIL 4 | $8.045 40.89% 230K
|
Information
MULN | News | $3.805 39.38% 11M
|
Information
RILY | $30.01 38.17% 11M
|
Finance
MTC | $3.04 35.71% 6.7M
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.